Illumina (ILMN) Q4 FY25 earnings call: guidance and Q&A

What is the 2026 operating margin exit rate, how does SomaLogic impact 2027 margin targets, and what are the capital deployment priorities including M&A criteria?

Management reaffirmed confidence in 2027 targets (high single-digit growth, 26% operating margin), noting SomaLogic is initially dilutive but synergies are being pursued. The CFO clarified that the 2026 exit rate for operating margin (ex-SomaLogic) would be higher than the full-year average. Capital deployment includes opportunistic share repurchases and M&A for long-term growth.

“We feel definitely still great about those targets. Just as a step back in '24, we were out there presenting that we would bring the business back to high single-digit growth by '27 and also delivering 500 basis points that should bring us to 26% operating margin.”

asked by Douglas Schenkel · answered by Jacob Thaysen

Why is the FY26 organic growth guidance (2-4% ex-China) a step down from the Q4 FY25 exit rate (7% ex-China), and was Q4 performance a one-off?

Management stated there is no fundamental step-down in momentum, especially in clinical (expecting mid-teens growth). Q4 is typically a strong quarter. The FY26 guidance averages H2 2025 performance (Q3 2% ex-China, Q4 7% ex-China) as a base, with continued caution in the research market offsetting clinical strength. NIH budget clarity is positive but fund flow remains uncertain.

“The way we have approached the guidance is to look at the half 2 of 2025 as we laid out during our Q3 earnings call, where in Q3, our growth was 2% ex-China. In Q4, up to 7%. And so we took the average for the second half to bracket our overall guidance.”

asked by Vijay Kumar · answered by Ankur Dhingra

What is the split of instrument placements between research and clinical, what is the context for the research market beyond academic pressure, and what is the competitive landscape for mid- and high-throughput instruments?

Over 60% of Q4 NovaSeq X placements were clinical, a trend expected to continue. The mid-throughput market remains muted due to macro trends. No significant competitive impact was observed in Q4, with strong interest in new launches like 5-base and spatial. The research outlook is primarily driven by the funding environment.

“As expected, more than 60% of those placements were related to clinical. And we expect that to be the case, that the dynamic to continue into '26, where clinical will be majority of the placements of instruments.”

asked by Puneet Souda · answered by Jacob Thaysen

How much of clinical growth is driven by mix versus volume, what is the status of Onso technology incorporation, and what is the expected revenue contribution from new adjacencies like spatial, constellation, and 5-base?

Clinical growth stems from both increased volume and higher sequencing intensity (e.g., larger panels, exome to whole genome), with intensity expected to be the main future driver. The Onso IP acquisition strengthens Illumina's portfolio and provides optionality. New adjacencies are in early stages and not expected to be meaningful for 2026 revenue, but are projected to contribute 1-2% growth in 2027 and beyond.

“I would say, over time, I think actually the intensity, meaning the larger panels is going to be the main growth driver going forward. We see a lot of opportunities there.”

asked by Tycho Peterson · answered by Jacob Thaysen

What is the update on China import conversations and potential outcomes, and how does Illumina plan to monetize BioInsight, given pharma enthusiasm and AI focus?

China represents less than 5% of the business, and Illumina is collaborating with Chinese regulators despite its UEL status, with potential upside if off the list. BioInsight, particularly the Billion Cell Atlas, has been well-received by pharma (AstraZeneca, Merck, Eli Lilly). Monetization will involve specialized data/AI tools and subscription models, a multi-year opportunity expected to contribute to growth from 2027.

“The monetization strategy here would be in 2 or 3 different ways. One is around very specialized data and AI tool constructions. And then over time, we see significant subscription-based models where we can help pharma companies, both on the discovery as well as on the development side of things.”

asked by Casey Woodring · answered by Ankur Dhingra

What are the conversations with academic core labs regarding instrument investments, the assumptions for academic consumables/instruments in guidance, Eric Green's role, and how Illumina's over-delivery on specs impacts competitive pricing claims?

Illumina has strong relationships with academic core labs, supporting them despite funding challenges. Eric Green's appointment aims to further aid navigation. While NIH funding clarity is positive, details are still pending. Illumina consistently over-delivers on instrument specifications, providing a direct cost reduction per gigabase for customers, which is a key competitive advantage against headline pricing claims.

“You are right that if you look at -- we have, and this is our -- we have a tradition for going out and deliver on par or better than our specs. This is something we're proud of and something that our customers know from Illumina is that we are not going out and commit to something we can't keep.”

asked by David Westenberg · answered by Jacob Thaysen